Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...

But they disagree on whether studying social genomics—elucidating any potential genetic contributions to behaviors ranging from mental illnesses to educational attainment to political affiliation—can ...